you are here: HomeNewsGepowerindia
management interviews
Jump to
9 Results Found
  • We are planning 6-8 new launches this fiscal yr: Alembic Pharma Jul 29, 2016 02:35 PM IST

    We are planning 6-8 new launches this fiscal yr: Alembic Pharma

    Speaking to CNBC-TV18 Pranav Amin, Managing Director of Alembic Pharmaceuticals, said that good Q1 numbers were led by international business. Sales of its anti-psychotic drug Abilify was one of the reasons the company saw higher sales, he said.

  • Alkem's brush with Germany may not hit profit, revenue:Prabhudas Apr 18, 2016 12:32 PM IST

    Alkem's brush with Germany may not hit profit, revenue:Prabhudas

    There is growing harmonisation between leading regulators across the world and WHO is taking note of the observations made by US FDA on pharma companies everywhere, says Surajit Pal, pharma analyst at Prabhudas Lilladher.

  • EBITDA margin came off unusually high base: Alembic Pharma Feb 04, 2015 03:14 PM IST

    EBITDA margin came off unusually high base: Alembic Pharma

    In an interview with CNBC-TV18‘s Ekta Batra and Reema Tendulkar, Pranav Amin, Director & President- International Business, Alembic Pharmaceuticals, discussed the company‘s quarterly earnings.

  • First launch in Algerian mkt seen in Q1FY16: Alembic Pharma Oct 28, 2014 12:34 PM IST

    First launch in Algerian mkt seen in Q1FY16: Alembic Pharma

    Once this deal is concluded, the company will be renamed as Alembic Mami SPA.

  • Alembic Pharma expects API biz to grow 10% in FY15 Oct 20, 2014 04:08 PM IST

    Alembic Pharma expects API biz to grow 10% in FY15

    The growth for the international generics, however, remain muted at about 9 percent due to higher base last year.

  • See 20% EBITDA growth in FY14: Alembic Pharma Aug 07, 2013 03:50 PM IST

    See 20% EBITDA growth in FY14: Alembic Pharma

    In an interview to CNBC-TV18, Amin adds that the company, despite the drug pricing policy, will grow at 15 percent.

  • Not impacted by Ranbaxy's negative news: Alembic Pharma May 29, 2013 04:38 PM IST

    Not impacted by Ranbaxy's negative news: Alembic Pharma

    Ranbaxy shares declined a further 2 percent on Wednesday morning after a media report said a prominent hospital in Mumbai had advised doctors to stop using the pharma company's drugs.

  • See 100-120 bps margin improvement in FY14: Alembic Pharma May 06, 2013 01:33 PM IST

    See 100-120 bps margin improvement in FY14: Alembic Pharma

    Alembic Pharma is hopeful to increase operating margin by 100-120 basis points in current financial year on the back of strong growth in international and domestic generic business.

  • ANDAs will benefit FY13 and FY14 numbers: Alembic Pharma Feb 09, 2012 02:16 PM IST

    ANDAs will benefit FY13 and FY14 numbers: Alembic Pharma

    Alembic Pharma has announced its third quarter results. Pranav Amin, director of Alembic Pharma says, the revenues have gone up 15%, YoY. He further says, the company so far has filed 41 abbreviated new drug applications (ANDAs). “Over the next couple of years, we should see quite a bit of growth coming in international generic,” he adds.

Sections